...
首页> 外文期刊>Cell metabolism >GDF-15 Neutralization Alleviates Platinum-Based Chemotherapy-Induced Emesis, Anorexia, and Weight Loss in Mice and Nonhuman Primates
【24h】

GDF-15 Neutralization Alleviates Platinum-Based Chemotherapy-Induced Emesis, Anorexia, and Weight Loss in Mice and Nonhuman Primates

机译:GDF-15中和减轻了小鼠和非人的衰减铂的化疗诱导的呕吐物,厌食症和减肥

获取原文
获取原文并翻译 | 示例
           

摘要

Platinum-based cancer therapy is restricted by dose-limiting side effects and is associated with elevation of growth differentiation factor 15 (GDF-15). But whether this elevation contributes to such side effects has been unclear. Here, we explored the effects of GDF-15 blockade on platinum-based chemotherapy-induced emesis, anorexia, and weight loss in mice and/or nonhuman primate models. We found that circulating GDF-15 is higher in subjects with cancer receiving platinum-based chemotherapy and is positively associated with weight loss in colorectal cancer (NCT00609622). Further, chemotherapy agents associated with high clinical emetic score induce circulating GDF-15 and weight loss in mice. Platinum-based treatment induced anorexia and weight loss are attenuated in GDF-15 knockout mice, while GDF-15 neutralization with the monoclonal antibody mAB1 improves survival. In nonhuman primates, mAB1 treatment attenuates anorexia and emesis. These results suggest that GDF-15 neutralization is a potential therapeutic approach to alleviate chemotherapy-induced side effects and improve the quality of life.
机译:以铂为基础的癌症治疗受到剂量限制性副作用的限制,并与生长分化因子15(GDF-15)的升高有关。但这种升高是否会导致此类副作用尚不清楚。在此,我们在小鼠和/或非人灵长类动物模型中探讨了GDF-15阻断剂对铂类化疗诱导的呕吐、厌食和体重减轻的影响。我们发现,接受铂类化疗的癌症患者的循环GDF-15水平较高,并且与结直肠癌患者的体重减轻呈正相关(NCT00609622)。此外,与高临床呕吐评分相关的化疗药物可诱导小鼠循环GDF-15和体重减轻。在GDF-15基因敲除小鼠中,以铂为基础的治疗诱导的厌食症和体重减轻得到缓解,而用单克隆抗体mAB1中和GDF-15可提高存活率。在非人灵长类动物中,mAB1治疗可减轻厌食和呕吐。这些结果表明,GDF-15中和是一种潜在的治疗方法,可以减轻化疗引起的副作用,提高生活质量。

著录项

  • 来源
    《Cell metabolism》 |2020年第6期|共20页
  • 作者单位

    Pfizer Inc Internal Med Res Unit 1 Portland St Cambridge MA USA;

    Pfizer Inc Internal Med Res Unit 1 Portland St Cambridge MA USA;

    Pfizer Inc Early Clin Dev Biostat 1 Portland St Cambridge MA USA;

    Pfizer Inc Internal Med Res Unit 1 Portland St Cambridge MA USA;

    Pfizer R&

    D UK Ltd Early Clin Dev Biostat Ramsgate Rd Sandwich Kent England;

    Pfizer Inc Internal Med Res Unit 1 Portland St Cambridge MA USA;

    Pfizer Inc Biomed Design 1 Portland St Cambridge MA USA;

    Pfizer Inc Internal Med Res Unit 1 Portland St Cambridge MA USA;

    Pfizer Inc Biomed Design 1 Burtt Rd Andover MA USA;

    Pfizer Inc Biomed Design 1 Portland St Cambridge MA USA;

    Pfizer Inc Biomed Design 1 Portland St Cambridge MA USA;

    Pfizer Inc Drug Safety Res &

    Dev 1 Portland St Cambridge MA USA;

    Pfizer Inc Internal Med Res Unit 1 Portland St Cambridge MA USA;

    Pfizer Inc Internal Med Res Unit 1 Portland St Cambridge MA USA;

    Pfizer Inc Biomed Design 1 Portland St Cambridge MA USA;

    Pfizer Inc Internal Med Res Unit 1 Portland St Cambridge MA USA;

    Pfizer Inc Internal Med Res Unit 1 Portland St Cambridge MA USA;

    Pfizer Inc Internal Med Res Unit 1 Portland St Cambridge MA USA;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 内分泌腺疾病及代谢病;
  • 关键词

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号